NIR-II photothermal therapy mediated by polymer-based nanoparticles to enhance checkpoint inhibitor immunotherapy for inhibiting lymph node metastasis in oral squamous cell carcinoma
Nano Today, ISSN: 1748-0132, Vol: 57, Page: 102351
2024
- 2Citations
- 4Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
New Findings in Oral Squamous Cell Carcinoma Described from Nanjing Medical University (Nir-ii Photothermal Therapy Mediated By Polymer-based Nanoparticles To Enhance Checkpoint Inhibitor Immunotherapy for Inhibiting Lymph Node Metastasis In ...)
2024 AUG 06 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on Oncology - Oral Squamous Cell Carcinoma have
Article Description
Oral squamous cell carcinoma (OSCC), a prevalent malignancy with high recurrence and metastasis rates, poses significant treatment challenges, particularly the prevention of lymph node metastasis. The development of a powerful photothermal agent for combined photothermal immunotherapy that inhibits OSCC metastasis remains challenging. Our study introduces an approach utilizing nanoparticles synthesized from a novel polymer with strong electron donor-acceptor structures for Near-Infrared II (NIR-II) photothermal therapy (PTT) by increasing intermolecular π-π interactions and enhancing non-radiative transitions. Owing to the superior tissue penetration capabilities of NIR-II region, these nanoparticles exhibit exceptional photothermal conversion, stability, and biocompatibility, making them ideal for deep-seated tumor ablation with minimal off-target effects. Mechanistically, the RNA-sequencing analysis revealed the upregulation of crucial apoptosis-related and antigen-presenting pathways in PTT-treated cancer cells. Polymer nanoparticles can intensify the immunogenic cell death to elicit a tumor-related immune response, releasing dramatically tumor-associated antigens, and activating damage-associated molecular patterns to eliminate tumor cells synergistically. As evidenced by our comprehensive in vivo OSCC mouse model, subsequent detailed approaches further demonstrated significant cancer cell eradication and induction of a strong immunogenic response to inhibit lymph node metastasis. Our study highlights the potential of tumor cell ablation and immunogenic activation dual therapy for targeting both primary and metastatic OSCC, suggesting a new direction for reshaping current therapeutic strategies for OSCC treatment.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1748013224002068; http://dx.doi.org/10.1016/j.nantod.2024.102351; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85195402468&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1748013224002068; https://dx.doi.org/10.1016/j.nantod.2024.102351
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know